1.44

2.70% -0.04

Compugen Ltd (CGEN)

Overview News Price History Option Chain Discussions Forecast

Compugen Ltd stock is traded at $1.44, with a volume of 75,249. It is down -2.70% in the last 24 hours and down -5.88% over the past month. Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Previous Close:

$1.48

Open:

$1.44

24h Volume:

75,249

Relative Volume:

0.19

Market Cap:

$129.98M

Revenue:

Net Income/Loss:

$1.60M

P/E Ratio:

48.00

EPS:

0.03

Net Cash Flow:

$-62.91M

1W Performance:

+3.60%

1M Performance:

-5.88%

6M Performance:

-14.79%

1Y Performance:

-25.00%

1-Day Range:

$1.42

$1.47

1-Week Range:

$1.38

$1.52

52-Week Range:

$1.13

$2.66

Compugen Ltd Stock (CGEN) Company Profile

Name

Compugen Ltd

Sector

Healthcare (1153)

Industry

Biotechnology (673)

Phone

Address

Employee

Twitter

@CompugenLtd

Next Earnings Date

2025-03-04

Latest SEC Filings

CGEN's Discussions on Twitter

Compare CGEN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CGEN Compugen Ltd	1.44	129.98M	0	1.60M	-62.91M	0.03
VRTX Vertex Pharmaceuticals Inc	496.49	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.86	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	620.97	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	254.85	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.46	24.70B	3.81B	-644.79M	-669.77M	-6.24

Compugen Ltd Stock (CGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-25	Initiated	Oppenheimer	Outperform
Aug-05-22	Downgrade	Jefferies	Buy → Hold
May-26-20	Resumed	JMP Securities	Mkt Outperform
May-13-20	Initiated	Stifel	Buy
May-07-20	Initiated	SVB Leerink	Outperform
Apr-22-20	Initiated	ROTH Capital	Buy
Mar-24-20	Initiated	SunTrust	Buy
Jan-16-20	Initiated	Cantor Fitzgerald	Overweight
Mar-29-18	Initiated	Oppenheimer	Outperform
Feb-01-16	Resumed	Oppenheimer	Outperform
Oct-15-15	Initiated	FBR Capital	Outperform
Apr-23-15	Resumed	Jefferies	Buy
Apr-21-15	Initiated	Oppenheimer	Outperform
Feb-07-14	Initiated	MLV & Co	Buy
Dec-28-09	Reiterated	Cantor Fitzgerald	Buy
Jul-29-09	Initiated	Cantor Fitzgerald	Buy

View All

Compugen Ltd Stock (CGEN) Latest News

Apr 24, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 24, 2025

Apr 13, 2025

67,041 Shares in Compugen Ltd. (NASDAQ:CGEN) Acquired by Raymond James Financial Inc. - Defense World

Apr 13, 2025

Compugen (NASDAQ:CGEN) vs. Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) Financial Review - Defense World

Apr 13, 2025

Apr 12, 2025

Commonwealth Equity Services LLC Takes Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World

Apr 12, 2025

Compugen Ltd. Announces Appointment of Alberto Sessa as Chief Financial Officer - marketscreener.com

Apr 12, 2025

Apr 09, 2025

Compugen at Stifel Forum: Strategic Insights on Immunotherapy Pipeline By Investing.com - Investing.com South Africa

Apr 09, 2025

Compugen at Stifel Forum: Strategic Insights on Immunotherapy Pipeline - Investing.com Australia

Apr 09, 2025

Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation? - simplywall.st

Apr 09, 2025

Apr 07, 2025

Compugen at Needham Conference: Strategic Immuno-Oncology Insights - Investing.com Australia

Apr 07, 2025

Compugen at Needham Conference: Strategic Immuno-Oncology Insights By Investing.com - Investing.com India

Apr 07, 2025

Apr 05, 2025

Compugen stock touches 52-week low at $1.35 amid market challenges - Investing.com Canada

Apr 05, 2025

Apr 04, 2025

Compugen stock touches 52-week low at $1.35 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 03, 2025

BeiGene stock slips on trial discontinuation (ONC:NASDAQ) - Seeking Alpha

Apr 03, 2025

Apr 02, 2025

Compugen at AI Drug Discovery Conference: Strategic Partnerships Drive Progress - Investing.com

Apr 02, 2025

Mar 26, 2025

Cancer AI Breakthrough: Compugen Takes Center Stage at 3 Elite Healthcare Forums - Stock Titan

Mar 26, 2025

Mar 23, 2025